BioInvent International
BioInvent International AB is a Swedish clinical-stage biopharmaceutical company focused on immuno-oncology cancer therapies. The company discovers and develops first-in-class monoclonal antibodies targeting tumor-associated myeloid cells and immunosuppressive receptors using its n-CoDeR library and F.I.R.S.T screening platform. Main revenue drivers comprise license fees, research collaboration payments, milestone compensation, and investment funding. BioInvent serves clinical oncology researchers, hospital networks, and global pharmaceutical partners across Europe and North America. The company holds an established niche position in European antibody-based immuno-oncology research and development. Headquartered in Lund, Sweden, BioInvent International AB is listed on Nasdaq Stockholm.
4 of the funds FundTelligence covers report a position in BioInvent International.
- Legal name
- BioInvent International AB
- Sector
- Health Care
- Country
- Sweden
- Funds holding it
- 4
Funds holding BioInvent International
- Lannebo Sweden Micro Cap — Lannebo · 0.28 % (full portfolio disclosed, June 2026)
- Handelsbanken Norden Index Criteria — Handelsbanken · 0.01 % (full portfolio disclosed, October 2026)
- Storebrand Sverige Småbolag Plus — Storebrand · 0.01 % (full portfolio disclosed, October 2026)
- Storebrand Sverige Plus — Storebrand · 0.0 % (full portfolio disclosed, October 2026)